Embryonal cancers in Europe
| Autor: | Rafael Marcos-Gragera, Eva Ardanaz, Magdalena Bielska-Lasota, Stanislaw Gozdz, Marina Vercelli, Pascale Grosclaude, Michel Coleman, Lucia Mangone, MARIA JOSE SANCHEZ-PEREZ, Juan Melchor, Gianni Bisogno, Andrea Ferrari, Diego Serraino, Giske Ursin, Maria Zwierko, Jan Willem Coebergh, Roberta De Angelis, Stefano Ferretti, Andrea Tavilla, Gemma Gatta, ANGELO DEI TOS, Fabio Falcini, Paolo Contiero, Rosario Tumino, Laufey Tryggvadottir, Jadwiga Rachtan, Alessandro Gronchi, Trama Annalisa, David Brewster |
|---|---|
| Přispěvatelé: | Usel, Massimo |
| Rok vydání: | 2012 |
| Předmět: |
Male
Hepatoblastoma Cancer Research Pediatrics Embryonal cancers incidence Time Factors Survival Pancreatoblastoma Neuroblastoma Outcome Assessment Health Care Prevalence Embryonal cancers Europe Registries Survivors Child Nephroblastoma Pulmonary blastoma education.field_of_study Geography Relative survival Retinoblastoma Incidence Incidence (epidemiology) Neoplasms Germ Cell and Embryonal Oncology Child Preschool Female Adult medicine.medical_specialty Adolescent Population Neoplasms Germ Cell and Embryonal/diagnosis/epidemiology NO Outcome Assessment (Health Care) Rare Diseases Rare Diseases/genetics medicine Humans education ddc:613 Population-based study business.industry Infant Newborn Infant Cancer medicine.disease Pulmonary Blastoma Neuroblastoma Nephroblastoma Retinoblastoma Hepatoblastoma Pulmonary blastoma Pancreatoblastoma Incidence Survival Prevalence Population-based study business |
| Zdroj: | European Journal of Cancer, Vol. 48, No 10 (2012) pp. 1425-33 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/j.ejca.2011.12.027 |
| Popis: | Embryonal cancers are a heterogeneous group of rare cancers which mainly occur in children and adolescents. The aim of the present study was to estimate the burden (incidence, prevalence, survival and proportion of cured) for the principal embryonal cancers in Europe (EU27), using population-based data from cancer registries (CRs) participating in RARECARE. We identified 3322 cases diagnosed from 1995 to 2002 (latest period for which data are available): 44% neuroblastoma, 35% nephroblastoma, 13% retinoblastoma and 6% hepatoblastoma. Very few cases of pulmonary blastoma (43 cases) and pancreatoblastoma (seven cases) were diagnosed. About 2000 new embryonal cancers were estimated every year in EU27, for an annual incidence rate of 4 per million (1.8 neuroblastoma, 1.4 nephroblastoma, and 0.5 retinoblastoma); 91% of cases occurred in patients under 15 years. Five-year relative survival for all embryonal cancers was 80% (99% retinoblastoma, 90% nephroblastoma, 71% hepatoblastoma and 68% neuroblastoma). Overall survival was lower in adolescents and adults than in those under 15 years. The cure rate was estimated at 80%. Slightly less than 40,000 persons were estimated alive in EU27 with a diagnosis of embryonal cancer in 2008. Nephroblastoma was the most prevalent (18,150 cases in EU27), followed by neuroblastoma (12,100), retinoblastoma (5200), hepatoblastoma (2700) and pulmonary blastoma (614). This is the first study to delineate the embryonal cancer burden in Europe by age, sex and European region. Survival/cure rate is generally high, but there are considerable gaps in our understanding of the natural histories of these rare diseases particularly in adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect